Voyager Therapeutics, Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing, not a standalone fourth-quarter report. Voyager is a preclinical-stage biotechnology company developing genetic medicines for neurological diseases, including Alzheimer’s disease, ALS, Parkinson’s disease and rare CNS disorders. Its programs use its TRACER AAV capsid platform and include wholly owned and partnered assets.
Financial results and liquidity
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Collaboration revenue | $250.0 million | $40.9 million |
| Research and development expense | $92.2 million | $60.8 million |
| General and administrative expense | $35.8 million | $31.0 million |
| Operating income (loss) | $122.0 million | $(50.8) million |
| Net income (loss) | $132.3 million | $(46.4) million |
| Net cash from (used in) operating activities | $77.9 million | $(12.5) million |
- Revenue rose by $209.1 million, chiefly from collaboration and license arrangements: $80.0 million recognized for the December 2023 Novartis agreement, $79.0 million from Novartis option exercises and an expired option, and $80.8 million from the 2023 Neurocrine agreement. Voyager reported no product sales.
- Net income and positive operating cash flow do not represent product-level profitability: results were driven by collaboration revenue, including license revenue recognized upon delivery of rights. The filing reports operating and net margins of approximately 48.8% and 52.9%, respectively, based on reported revenue; these margins are highly affected by collaboration accounting and are not evidence of recurring product economics.
- R&D spending increased 51.7% year over year, mainly due to higher staffing and external program costs, including manufacturing and IND-enabling work. G&A rose 15.6%.
- At year-end, cash and cash equivalents were $68.8 million and marketable securities were $162.1 million, totaling $230.9 million. Accounts receivable was $80.2 million, primarily the Novartis upfront payment collected in January 2024. Current assets were $319.7 million against current liabilities of $64.5 million.
- Operating cash flow included a substantial accounts-receivable increase; investing cash outflow was $141.6 million, mainly net purchases of marketable securities; financing cash inflow was $33.6 million, primarily Neurocrine’s 2023 equity investment. The filing lists no borrowings; lease liabilities and other contractual obligations remain.
- Year-end total liabilities were $115.0 million and stockholders’ equity was $236.3 million. Deferred revenue totaled $75.2 million. The company reported an accumulated deficit of $261.2 million.
Material changes and notable transactions
- Voyager moved from a $46.4 million net loss in 2022 to $132.3 million net income in 2023, primarily because of collaboration/license revenue recognition; it continues to expect operating losses as development costs rise.
- In January 2023, Voyager entered a new Neurocrine collaboration covering GBA1 and three rare-target discovery programs. Neurocrine paid approximately $136.0 million upfront and approximately $39.0 million for equity; the agreement also provides for substantial potential milestones and royalties, subject to development and commercial success.
- In December 2023, Voyager signed a Novartis collaboration covering spinal muscular atrophy capsid rights and Huntington’s disease development. It provides an $80.0 million upfront payment, potential development and sales milestones, and tiered royalties. The upfront was recognized as revenue in 2023 but collected in January 2024.
- In January 2024, Voyager received approximately $20.0 million from a Novartis share purchase and approximately $93.5 million net proceeds from a public offering of shares and pre-funded warrants. These transactions occurred after year-end and increased potential dilution.
- In February 2024, Neurocrine selected a Friedreich’s ataxia development candidate, triggering a $5.0 million milestone expected in the first quarter of 2024.
Outlook, management commentary and risks
- Management estimates year-end 2023 liquidity, together with the subsequent Novartis payment and investment, January 2024 offering proceeds, expected collaboration reimbursements, certain near-term milestones and interest income, will fund planned operating expenses and capital requirements into 2027. This is an estimate dependent on the operating plan and anticipated receipts, not a guarantee.
- Prioritized wholly owned programs are an anti-tau antibody for Alzheimer’s (IND targeted for first half of 2024), SOD1 silencing gene therapy for ALS (IND targeted for mid-2025), and tau silencing gene therapy for Alzheimer’s (IND targeted for 2026). These timelines are forward-looking; all active candidates were preclinical or advancing toward the clinic at filing.
- Management expects increased R&D and operating costs as programs advance. Voyager has not generated product revenue and expects to require additional funding over time; unavailable or unfavorable financing could force delays, reductions or discontinuations.
- Key risks include uncertain safety, efficacy and regulatory pathways for gene therapies; dependence on collaborators for funding and development; manufacturing complexity and reliance on third parties, including a sole supplier for certain vectors; competition; intellectual-property challenges; and potential dilution from future equity financing.
- Revenue recognition relies partly on estimates of costs remaining to complete collaboration services. The auditor identified proportional-performance revenue recognition as a critical audit matter because changes in those estimates can materially affect revenue timing.
- No material legal proceedings were reported at December 31, 2023. The auditor issued an unqualified opinion on the financial statements; management concluded disclosure controls and internal control over financial reporting were effective.
Most important facts for investors to verify
- Whether projected IND, clinical-trial and partnered-program milestones are achieved on schedule, and whether preclinical findings translate to human safety and biological activity.
- How much of future revenue and cash flow depends on collaboration payments, cost reimbursements, option exercises and milestone achievement, rather than product sales.
- The assumptions supporting the stated cash runway into 2027, including spending plans, collaborator reimbursements, milestone receipts and further financing needs.
- Quarterly collaboration revenue recognition, deferred revenue, receivables and remaining-cost estimates under the proportional-performance model.
- The effect of the January 2024 equity offering, pre-funded warrants and other equity awards on fully diluted share count and per-share value.
- Partner priorities, termination rights, and the timing and conditions attached to potential milestone and royalty payments; headline maximum payments are contingent, not assured.